143 related articles for article (PubMed ID: 30229418)
1. Resectable Distal Pancreas Cancer: Time to Reconsider the Role of Upfront Surgery.
Nelson DW; Chang SC; Grunkemeier G; Dehal AN; Lee DY; Fischer TD; DiFronzo LA; O'Connor VV
Ann Surg Oncol; 2018 Dec; 25(13):4012-4019. PubMed ID: 30229418
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis.
de Geus SW; Eskander MF; Bliss LA; Kasumova GG; Ng SC; Callery MP; Tseng JF
Surgery; 2017 Mar; 161(3):592-601. PubMed ID: 28341441
[TBL] [Abstract][Full Text] [Related]
3. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.
Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB
Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.
Mokdad AA; Minter RM; Zhu H; Augustine MM; Porembka MR; Wang SC; Yopp AC; Mansour JC; Choti MA; Polanco PM
J Clin Oncol; 2017 Feb; 35(5):515-522. PubMed ID: 27621388
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant
Hashmi A; Kozick Z; Fluck M; Hunsinger MA; Wild J; Arora TK; Shabahang MM; Blansfield JA
Am Surg; 2018 Sep; 84(9):1439-1445. PubMed ID: 30268172
[TBL] [Abstract][Full Text] [Related]
6. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study.
Bergquist JR; Puig CA; Shubert CR; Groeschl RT; Habermann EB; Kendrick ML; Nagorney DM; Smoot RL; Farnell MB; Truty MJ
J Am Coll Surg; 2016 Jul; 223(1):52-65. PubMed ID: 27049786
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.
Roland CL; Yang AD; Katz MH; Chatterjee D; Wang H; Lin H; Vauthey JN; Pisters PW; Varadhachary GR; Wolff RA; Crane CH; Lee JE; Fleming JB
Ann Surg Oncol; 2015 Apr; 22(4):1168-75. PubMed ID: 25352267
[TBL] [Abstract][Full Text] [Related]
8. External radiation is associated with limited improvement in overall survival in resected margin-negative stage IIB pancreatic adenocarcinoma.
Kantor O; Talamonti MS; Lutfi W; Wang CH; Winchester DJ; Marsh R; Prinz RA; Baker MS
Surgery; 2016 Dec; 160(6):1466-1476. PubMed ID: 27614417
[TBL] [Abstract][Full Text] [Related]
9. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
10. Histopathological tumour viability after neoadjuvant chemotherapy influences survival in resected pancreatic cancer: analysis of early outcome data.
Townend P; de Reuver PR; Chua TC; Mittal A; Clark SJ; Pavlakis N; Gill AJ; Samra JS
ANZ J Surg; 2018 Mar; 88(3):E167-E172. PubMed ID: 28318082
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreatic Cancer - A Matched-Pair Analysis.
Timmermann L; Rosumeck N; Klein F; Pratschke J; Pelzer U; Bahra M; Malinka T
Anticancer Res; 2019 Oct; 39(10):5781-5787. PubMed ID: 31570482
[TBL] [Abstract][Full Text] [Related]
12. National Trends in the Use of Neoadjuvant Chemotherapy for Hormone Receptor-Negative Breast Cancer: A National Cancer Data Base Study.
Puig CA; Hoskin TL; Day CN; Habermann EB; Boughey JC
Ann Surg Oncol; 2017 May; 24(5):1242-1250. PubMed ID: 28000076
[TBL] [Abstract][Full Text] [Related]
13. Value of lymph node positivity in treatment planning for early stage pancreatic cancer.
Tran Cao HS; Zhang Q; Sada YH; Silberfein EJ; Hsu C; Van Buren G; Chai C; Katz MHG; Fisher WE; Massarweh NN
Surgery; 2017 Sep; 162(3):557-567. PubMed ID: 28666686
[TBL] [Abstract][Full Text] [Related]
14. Correlation of clinical and pathological staging and response to neoadjuvant therapy in resected pancreatic cancer.
Mirkin KA; Greenleaf EK; Hollenbeak CS; Wong J
Int J Surg; 2018 Apr; 52():221-228. PubMed ID: 29425826
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant therapy versus upfront surgery for early-stage left-sided pancreatic adenocarcinoma: A propensity-matched analysis from a national cohort of distal pancreatectomies.
Nassour I; Adam MA; Kowalsky S; Al Masri S; Bahary N; Singhi AD; Lee K; Zureikat A; Paniccia A
J Surg Oncol; 2021 Jan; 123(1):245-251. PubMed ID: 33103242
[TBL] [Abstract][Full Text] [Related]
16. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
[TBL] [Abstract][Full Text] [Related]
17. The impact of chemotherapy sequencing on resectable pancreatic cancer by stage.
Vega EA; Kutlu OC; Salehi O; Alarcon SV; Abudalou M; Kozyreva O; Krishnan S; Lee D; Freeman R; Conrad C
Surg Oncol; 2022 Mar; 40():101694. PubMed ID: 34973593
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer.
Nurmi A; Mustonen H; Parviainen H; Peltola K; Haglund C; Seppänen H
Acta Oncol; 2018 Jun; 57(6):799-806. PubMed ID: 29241394
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Chemotherapy Versus Upfront Surgery for Resectable Pancreatic Adenocarcinoma: An Updated Nationwide Study.
Sugawara T; Rodriguez Franco S; Sherman S; Torphy RJ; Colborn K; Franklin O; Ishida J; Grandi S; Al-Musawi MH; Gleisner A; Schulick RD; Del Chiaro M
Ann Surg; 2024 Feb; 279(2):331-339. PubMed ID: 37226812
[TBL] [Abstract][Full Text] [Related]
20. Trends in the treatment of resectable pancreatic adenocarcinoma.
Raigani S; Ammori J; Kim J; Hardacre JM
J Gastrointest Surg; 2014 Jan; 18(1):113-23. PubMed ID: 24002769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]